Navigation Links
Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
Date:4/22/2008

from GSK. The companies will share equally in Phase 3/4 development costs, sales and marketing expenses, and profits of any product commercialized under the agreement.

About Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic, life-threatening autoimmune disease. Approximately 1.5 million people in the United States and approximately 5 million worldwide suffer from various forms of lupus, including SLE. Lupus can occur at any age, but appears mostly in young people ages 15 to 45. About 90 percent of those diagnosed with lupus are women. African-American women are about three times more likely to develop lupus, and it is also more common in Hispanic, Asian and American Indian women. Symptoms may include extreme fatigue, painful and swollen joints, unexplained fever, skin rash, and kidney problems. Lupus can lead to arthritis, kidney failure, heart and lung inflammation, central nervous system abnormalities, inflammation of the blood vessels, and blood disorders. For more information on lupus, visit the Lupus Foundation of America at http://www.lupus.org or the European Lupus Erythematosus Federation at http://www.elef.rheumanet.org .

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to be
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
2. Data Show SuperGens MP-470 is Safe in Humans
3. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
4. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
5. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
6. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
7. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 20, 2013  Whole-cell pertussis vaccines were more effective ... a large recent outbreak, according to a new Kaiser ... vaccines, also called DTwP, were available from the 1940s ... ultimately led to the development of acellular pertussis vaccines, ... the United States had switched ...
(Date:5/18/2013)... Fla. , May 18, 2013 Although ... and are considered the most sensitive method for detecting ... effective in preventing cancer cases 3 . EndoChoice ® ... new Fuse™ system significantly improves the accuracy of this ... by colonoscopists. EndoChoice will be discussing these clinical trial ...
(Date:5/18/2013)... 2013 Faruqi & Faruqi, LLP, a ... securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses ... federal securities laws by issuing materially false and/or ... trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, the ...
Breaking Medicine Technology:Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 2Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 3Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak 4New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
(Date:5/20/2013)... Wolters Kluwer Health is pleased to announce ... journals won 13 ASHPE awards in 10 categories. ... publications for editorial, design, print and online award ... recognized year after year for delivering high-quality publications ... quality, depth, and impact," said Jayne Marks, Vice ...
(Date:5/20/2013)... May 20, 2013 Join Seva Foundation in ... at the Palace of Fine Arts Theater in ... , C.C. White and Shimshai, with host Wavy Gravy. All ... world. , Reserved seats are $40 & $55, ... the artists and a front row seat at the show. ...
(Date:5/20/2013)... Ponte Vedra Beach, Florida (PRWEB) May 20, 2013 ... healthcare value and market access, is pleased to present ... the Health Outcomes community. HE-Xpo vastly expands the ... utilizing an intuitive, web-based platform with the look, feel, ... to the global community of pharmaceutical professionals twenty-four hours ...
(Date:5/20/2013)... A new Benefits of Pharmacy Home Delivery report ... MedEx Pack announced. The new report offers ... order to provide useful details for those who are contemplating ... MedEx Direct owner and pharmacist said, “One of the biggest ... like the MedEx Pack, patients can receive their own pre-filled ...
(Date:5/20/2013)... Fresno, CA (PRWEB) May 20, 2013 It’s ... a chance, there’s still time to bust out those dusty ... going to have a little cross-company challenge in the office ... to see who can log the most pledged miles for ... building, but they’ll never share their miles! , *insert battle ...
Breaking Medicine News(10 mins):Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2Health News:Memorial Day Kirtan Concert Palace of Fine Arts Theater in San Francisco Featuring: Snatam Kaur, Jai Uttal, C.C. White & Shimshai with host Wavy Gravy,May 27th 7:00 PM 2Health News:HealthEconomics.Com Launches HE-Xpo, an Online Virtual Trade Show, Educational Center and Exhibit Hall at Major Pharmaceutical Industry Meeting 2Health News:HealthEconomics.Com Launches HE-Xpo, an Online Virtual Trade Show, Educational Center and Exhibit Hall at Major Pharmaceutical Industry Meeting 3Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2
... not met in your regular job, German research shows , ... health benefits and may even help you perform better in ... , The study included 105 people who worked an average ... of 6.7 hours per week volunteering in activities ranging from ...
... ... launch of a project with Embark Health, Inc. This new ventures is dedicated to ... ... Jellyvision Lab, pioneers of Interactive Conversation , is pleased to announce the launch of ...
... , NEW YORK , Feb. 16 ... of health information, today announced a set of new enhancements ... at the point-of-care. Medscape Mobile, WebMD,s free medical application for ... articles on diseases, conditions, and procedures, in addition to complete ...
... (WHI) confirm that combination hormone therapy increases the risk of ... trend toward an increased risk of heart disease during the ... therapy within 10 years of menopause, and a more marked ... than 10 years after menopause. Analyses indicate that overall ...
... disease activity when added to interferon beta , TUESDAY, ... to standard treatment with interferon beta may reduce multiple ... new study reports. , Previous non-randomized studies found that ... disease activity. , This new phase 2 study ...
... ... ... -- Aberdeen Group, a Harte-Hanks Company has released a new benchmark report entitled Recovering ... (TEM) solutions as a strategic foundation and precursor for other communications and network ...
Cached Medicine News:Health News:Volunteering Can Bring Rewards Even in the Workplace 2Health News:Embark Health Selects the Jellyvision Lab's Interactive Conversation Technology to Educate Website Visitors on Advance Directives 2Health News:Embark Health Selects the Jellyvision Lab's Interactive Conversation Technology to Educate Website Visitors on Advance Directives 3Health News:Embark Health Selects the Jellyvision Lab's Interactive Conversation Technology to Educate Website Visitors on Advance Directives 4Health News:WebMD Launches New Version of Free Mobile Application for Physicians 2Health News:WebMD Launches New Version of Free Mobile Application for Physicians 3Health News:WebMD Launches New Version of Free Mobile Application for Physicians 4Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Added Drug Aids MS Treatment 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 3Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 4Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 5
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... 12 Plus is a hematology control for ... Assay values are provided for the five-part ... three-part differential on the CELL-DYN 1600 and ... closed-vial stability is 75 days. Para 12 ...
... Release Technology essentially eliminates premature deployment ... anatomically designed tapered stent for better ... Rapid Exchange catheter with 6 Fr ... tip,, Radiopaque marker on catheter clearly ...
... 5-part differential control that controls all parameters, ... LH 750/LH 755, MAXM and HmX instruments. ... values for all three levels. White blood ... are within clinically significant ranges. This unique ...
Medicine Products: